Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.
The patent granted by the USPTO covers the use of biomarkers in determining the efficacy of SPC-15, a targeted prophylactic treatment using ketamine compositions, as a method of treatment for stress-induced affective disorders or stress-induced psychopathology.
Silo’s CEO Eric Weisblum says the patent is “an important addition” to the company’s IP, by …